top of page
10 Feb 2022
Afferent Medical Solutions announces MHRA approval of SCRATCH-HTN Ph.II sham-controlled randomized control trial evaluating the safety, acceptability and efficacy of autonomic neuromodulation using trans-cutaneous auricular sensory stimulation in uncontrolled hypertensive patients
Afferent Medical Solutions announces MHRA approval of SCRATCH-HTN Ph.II sham-controlled randomized control trial evaluating the safety, acceptability and efficacy of autonomic neuromodulation using trans-cutaneous auricular sensory stimulation in uncontrolled hypertensive patients
bottom of page